Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50-Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $2.95 and traded as low as $2.02. Voyager Therapeutics shares last traded at $2.19, with a volume of 1,114,228 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts recently commented on VYGR shares. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Voyager Therapeutics Trading Down 7.9%

The firm has a fifty day moving average price of $2.90 and a 200-day moving average price of $3.36.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. The business had revenue of $3.17 million during the quarter, compared to the consensus estimate of $4.52 million. Research analysts expect that Voyager Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth about $18,102,000. Renaissance Technologies LLC grew its holdings in Voyager Therapeutics by 95.0% in the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock valued at $2,231,000 after purchasing an additional 281,574 shares during the period. Bank of New York Mellon Corp purchased a new stake in Voyager Therapeutics in the second quarter valued at approximately $513,000. Seven Fleet Capital Management LP grew its holdings in Voyager Therapeutics by 100.0% in the second quarter. Seven Fleet Capital Management LP now owns 230,406 shares of the company’s stock valued at $772,000 after purchasing an additional 115,203 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC increased its position in Voyager Therapeutics by 100.3% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 205,732 shares of the company’s stock worth $794,000 after purchasing an additional 103,016 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company uses its proprietary TRACER capsid discovery platform to identify adeno-associated virus (AAV) capsids designed to improve the delivery of genetic medicines to the brain and central nervous system.

Voyager’s research and development programs have addressed conditions including Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and Friedreich’s ataxia.